The Journal of Heart and Lung Transplantation
Volume 29, Issue 4, Supplement , Pages S1-S39 , April 2010

Clinical management of continuous-flow left ventricular assist devices in advanced heart failure

  • Mark S. Slaughter, MD

      Affiliations

    • University of Louisville, Louisville, Kentucky
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Francis D. Pagani, MD

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Joseph G. Rogers, MD

      Affiliations

    • Duke University, Durham, North Carolina
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Leslie W. Miller, MD

      Affiliations

    • Georgetown University, Washington Hospital, Washington, District of Columbia
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Benjamin Sun, MD

      Affiliations

    • Ohio State University, Columbus, Ohio
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Stuart D. Russell, MD

      Affiliations

    • Johns Hopkins Hospital, Baltimore, Maryland
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Randall C. Starling, MD, M.P.H.

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • Drs. Slaughter, Pagani, Rogers, Miller, Sun, Russell, and Starling contributed equally to this article
    • ,
  • Leway Chen, MD

      Affiliations

    • University of Rochester, Rochester, New York
    • ,
  • Andrew J. Boyle, MD

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Suzanne Chillcott, RN

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
    • ,
  • Robert M. Adamson, MD

      Affiliations

    • Sharp Memorial Hospital, San Diego, California
    • ,
  • Margaret S. Blood, RN

      Affiliations

    • University of Alabama, Birmingham, Alabama
    • ,
  • Margarita T. Camacho, MD

      Affiliations

    • Beth Israel Medical Center, Newark, New Jersey
    • ,
  • Katherine A. Idrissi, RN, MSN

      Affiliations

    • Columbia University, New York, New York
    • ,
  • Michael Petty, RN, PhD

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Michael Sobieski, RN, CCP

      Affiliations

    • University of Louisville, Louisville, Kentucky
    • ,
  • Susan Wright, RN, BSN, CCRN

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Timothy J. Myers, BS, CRA

      Affiliations

    • Houston, Texas
    • ,
  • David J. Farrar, PhD

      Affiliations

    • Thoratec Corporation, Pleasanton, California
    • Corresponding Author InformationReprint requests: Dr David J. Farrar, Thoratec Corporation, 6035 Stoneridge Dr, Pleasanton, CA 94588. Fax: 925-847-8574
    • ,
  • HeartMate II Clinical Investigators

Received 13 January 2010 ,Accepted 17 January 2010.

References 

  1. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251
  2. Goldstein D, Zucker M, Pagani FD, Frazier OH. Rotary ventricular assist devices. In:  Kirklin JK,  Frazier OH editor. ISHLT monograph series: mechanical circulatory support. New York: Elsevier; 2006;p. 77–104
  3. Lahpor J. State of the art: implantable ventricular assist devices. Curr Opin Organ Transplant. 2009;1:6
  4. John R. Current axial-flow devices—the HeartMate II and Jarvik 2000 left ventricular assist devices. Semin Thorac Cardiovasc Surg. 2008;20:264–272
  5. Simon MA, Watson J, Baldwin JT, Wagner WR, Borovetz HS. Current and future considerations in the use of mechanical circulatory support devices. Annu Rev Biomed Eng. 2008;10:59–84
  6. Kirklin JK, Holman WL. Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol. 2006;21:120–126
  7. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–896
  8. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–321
  9. Fang JC. Rise of the machines—left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med. 2009;361:1–3
  10. Advanced practice guidelines for HeartMate destination therapy. Vol 1. Pleasanton, CA: Thoratec Corporation; 2004.
  11. Advanced practice guidelines for HeartMate destination therapy. Vol 2. Pleasanton, CA: Thoratec Corporation; 2004.
  12. Westaby S, Siegenthaler M, Beyersdorf F, et al. Destination therapy with a rotary blood pump and novel power delivery. Eur J Cardiothorac Surg. 2009;[in press, doi:10.1016/j.ejcts.2009.03.071]
  13. Morshuis M, El-Banayosy A, Arusoglu L, et al. European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg. 2009;35:1020–1027discussion 1027-8
  14. Loforte A, Montalto A, Ranocchi F, et al. HeartMate II axial-flow left ventricular assist system: management, clinical review and personal experience. J Cardiovasc Med (Hagerstown). 2009;10:765–771
  15. Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2009;[in press, doi:10.1016/j.ejcts.2009.05.043]
  16. Strueber M, Birks E, Jansz P, O'Driscoll G, Wiesenthaler G. Clinical results of the international HeartWare LVAS bridge to transplant trial. J Heart Lung Transplant. 2009;28:S255
  17. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–2667
  18. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424–1433
  19. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?. J Heart Lung Transplant. 2009;28:231–236
  20. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29:1–10
  21. Holman WL, Pae WE, Teutenberg JJ, et al. INTERMACS: interval analysis of registry data. J Am Coll Surg. 2009;208:755–761discussion 61-2
  22. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535–541
  23. Farrar DJ. Preoperative predictors of survival in patients with Thoratec ventricular assist devices as a bridge to heart transplantation (Thoratec Ventricular Assist Device Principal Investigators). J Heart Lung Transplant. 1994;13:93–100; discussion 101
  24. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation. 1995;92:II169–II173
  25. Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg. 2003;125:855–862
  26. Lin CY, Tsai FC, Tian YC, et al. Evaluation of outcome scoring systems for patients on extracorporeal membrane oxygenation. Ann Thorac Surg. 2007;84:1256–1262
  27. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505
  28. Mano A, Fujita K, Uenomachi K, et al. Body mass index is a useful predictor of prognosis after left ventricular assist system implantation. J Heart Lung Transplant. 2009;28:428–433
  29. Holdy K, Dembitsky W, Eaton LL, et al. Nutrition assessment and management of left ventricular assist device patients. J Heart Lung Transplant. 2005;24:1690–1696
  30. Lockard KL, Degore L, Schwarm P, et al. Lack of improvement in prealbumin at two weeks predicts a poor outcome after mechanical circulatory support. J Heart Lung Transplant. 2009;28:S66
  31. Farrar DJ, Compton PG, Hershon JJ, Fonger JD, Hill JD. Right heart interaction with the mechanically assisted left heart. World J Surg. 1985;9:89–102
  32. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122:1186–1195
  33. Farrar DJ, Hill JD, Pennington DG, et al. Preoperative and postoperative comparison of patients with univentricular and biventricular support with the Thoratec ventricular assist device as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg. 1997;113:202–209
  34. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous flow left ventricular assist device: incidence, risk factors, and impact on outcomes. J Thorac Cardiovasc Surg. 2010;[in press]
  35. Fitzpatrick JR, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27:1286–1292
  36. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–2172
  37. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation. 2002;106:I198–I202
  38. Schenk S, McCarthy PM, Blackstone EH, et al. Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. J Thorac Cardiovasc Surg. 2006;131:447–454
  39. Loforte A, Potapov E, Krabatsch T, et al. Levitronix CentriMag to Berlin Heart Excor: a “bridge to bridge” solution in refractory cardiogenic shock. ASAIO J. 2009;55:465–468
  40. Haj-Yahia S, Birks EJ, Amrani M, et al. Bridging patients after salvage from bridge to decision directly to transplant by means of prolonged support with the CentriMag short-term centrifugal pump. J Thorac Cardiovasc Surg. 2009;138:227–230
  41. Gregoric ID, Jacob LP, La Francesca S, et al. The TandemHeart as a bridge to a long-term axial-flow left ventricular assist device (bridge to bridge). Tex Heart Inst J. 2008;35:125–129
  42. Farrar DJ. The Thoratec ventricular assist device: a paracorporeal pump for treating acute and chronic heart failure. Semin Thorac Cardiovasc Surg. 2000;12:243–250
  43. Fitzpatrick JR, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971–977
  44. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157
  45. Klodell CT, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007;83:68–71; discussion
  46. Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg. 2009;87:1072–1078
  47. Ma L, Fujino Y, Matsumiya G, Sawa Y, Mashimo T. Renal function with left ventricular assist devices: the poorer the preoperative renal function, the longer the recovery. Med Sci Monit. 2008;14:CR621–CR627
  48. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745–1751
  49. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612
  50. Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann Thorac Surg. 2003;75:S29–S35
  51. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation. 2009;120:2352–2357
  52. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28:881–887
  53. Reinhartz O, Farrar DJ, Hershon JH, Avery GJ, Haeusslein EA, Hill JD. Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation. J Thorac Cardiovasc Surg. 1998;116:633–640
  54. Radovancevic B, Vrtovec B, de Kort E, Radovancevic R, Gregoric ID, Frazier OH. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant. 2007;26:815–818
  55. Letsou GV, Myers TJ, Gregoric ID, et al. Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann Thorac Surg. 2003;76:1167–1170
  56. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?. Ann Thorac Surg. 2009;87:1633–1640
  57. Morel-Kopp MC, Aboud M, Tan CW, Kulathilake C, Ward C, et al. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res. 2010;[in press, doi:10.1016/j.thromres.2009.12.001]
  58. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol 201023:74-9.
  59. Kormos RL, Teuteberg JJ, Siegenthaler MP, et al. Pre-VAD implant risk factors influence the onset of adverse events (AEs) while on VAD. J Heart Lung Transplant. 2009;28:S153
  60. Chinn R, Dembitsky W, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 2005;51:461–470
  61. Tylus-Earl N, Chillcott S. Mental health and medical challenges (Management of a depressed patient with a left ventricular assist system in an inpatient psychiatric setting). J Psychosoc Nurs Ment Health Serv. 2009;47:43–49; quiz 51
  62. Pal JD, Klodell CT, John R, et al. Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation. 2009;120:S215–S219
  63. Mudd JO, Cuda JD, Halushka M, Soderlund KA, Conte JV, Russell SD. Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. J Heart Lung Transplant. 2008;27:1269–1274
  64. Matthews JC, Aaronson KD, Jain R, Pagani FD, Kolias TJ. Aortic insuffciency—trends over time in LVAD supported patient. J Heart Lung Transplant. 2009;28:S306
  65. Haghi D, Suselbeck T, Saur J. Aortic regurgitation during left ventricular assist device support. J Heart Lung Transplant. 2007;26:1220–1221
  66. Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). J Thorac Cardiovasc Surg. 2004;127:264–266
  67. Stringham JC, Bull DA, Karwande SV. Patch closure of the aortic anulus in a recipient of a ventricular assist device. J Thorac Cardiovasc Surg. 2000;119:1293–1294
  68. Rao V, Slater JP, Edwards NM, Naka Y, Oz MC. Surgical management of valvular disease in patients requiring left ventricular assist device support. Ann Thorac Surg. 2001;71:1448–1453
  69. Feldman CM, Silver MA, Sobieski MA, Slaughter MS. Management of aortic insufficiency with continuous flow left ventricular assist devices: bioprosthetic valve replacement. J Heart Lung Transplant. 2006;25:1410–1412
  70. Butany J, Leong SW, Rao V, et al. Early changes in bioprosthetic heart valves following ventricular assist device implantation. Int J Cardiol. 2007;117:e20–e23
  71. HeartMate II LVAS: Instructions for use. Pleasanton, CA: Thoratec Corporation; 2008.
  72. Chen JM, Rose EA. Management of perioperative right-sided circulatory failure. In:  Goldstein DJ,  Oz M editor. Cardiac assist devices. Armonk, NY: Futura Publishing Co Inc; 2000;p. 83–101
  73. Nakashima K, Kirsch ME, Vermes E, Rosanval O, Loisance D. Off-pump replacement of the INCOR implantable axial-flow pump. J Heart Lung Transplant. 2009;28:199–201
  74. Frazier OH, Gregoric ID, Cohn WE. Initial experience with non-thoracic, extraperitoneal, off-pump insertion of the Jarvik 2000 Heart in patients with previous median sternotomy. J Heart Lung Transplant. 2006;25:499–503
  75. Sun BC, Firstenberg MS, Louis LB, et al. Placement of long-term implantable ventricular assist devices without the use of cardiopulmonary bypass. J Heart Lung Transplant. 2008;27:718–721
  76. Augoustides JG, Ochroch EA. Inhaled selective pulmonary vasodilators. Int Anesthesiol Clin. 2005;43:101–114
  77. Augoustides JG, Ochroch EA. Pro: inhaled prostaglandin as a pulmonary vasodilator instead of nitric oxide. J Cardiothorac Vasc Anesth. 2005;19:400–402
  78. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127:1058–1067
  79. Dickstein ML. Con: inhaled prostaglandin as a pulmonary vasodilator instead of nitric oxide. J Cardiothorac Vasc Anesth. 2005;19:403–405
  80. Tector AJ, Kress DC, Downey FX, Schmahl TM, Dasse KA, Poirier VL. Transition from cardiopulmonary bypass to the HeartMate left ventricular assist device. Ann Thorac Surg. 1998;65:643–646
  81. Stainback RF, Croitoru M, Hernandez A, Myers TJ, Wadia Y, Frazier OH. Echocardiographic evaluation of the Jarvik 2000 axial-flow LVAD. Tex Heart Inst J. 2005;32:263–270
  82. Catena E, Milazzo F. Echocardiography and cardiac assist devices. Minerva Cardioangiol. 2007;55:247–265
  83. Chumnanvej S, Wood MJ, MacGillivray TE, Melo MF. Perioperative echocardiographic examination for ventricular assist device implantation. Anesth Analg. 2007;105:583–601
  84. Augoustides JG. Perioperative echocardiographic assessment of left ventricular assist device implantation: additional causes of inflow cannula obstruction. Anesth Analg. 2008;106:673–674; author reply 4
  85. Gregoric ID. Exchange techniques for implantable ventricular assist devices. ASAIO J. 2008;54:14–19
  86. Gregoric ID, Bruckner BA, Jacob L, et al. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Ann Thorac Surg. 2008;85:1646–1649
  87. La Francesca S, Smith R, Gregoric ID, et al. Replacement of a malfunctioning HeartMate II left ventricular assist device in a 14-year-old after a sudden fall. J Heart Lung Transplant. 2006;25:862–864
  88. Lodge AJ. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device (Invited commentary). Ann Thorac Surg. 2008;85:1650
  89. Letsou GV, Connelly JH, Delgado RM, et al. Is native aortic valve commissural fusion in patients with long-term left ventricular assist devices associated with clinically important aortic insufficiency?. J Heart Lung Transplant. 2006;25:395–399
  90. Banchs JE, Dawn B, Abdel-Latif A, et al. Acquired aortic cusp fusion after chronic left ventricular assist device support. J Am Soc Echocardiogr. 2006;19:1401;e1-3
  91. Amir O, Bracey AW, Smart FW, Delgado RM, Shah N, Kar B. A successful anticoagulation protocol for the first HeartMate II implantation in the United States. Tex Heart Inst J. 2005;32:399–401
  92. Frazier OH, Delgado RM, Kar B, Patel V, Gregoric ID, Myers TJ. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report. Tex Heart Inst J. 2004;31:157–159
  93. John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;136:1318–1323
  94. Struber M, Sander K, Lahpor J, et al. HeartMate II left ventricular assist device; early European experience. Eur J Cardiothorac Surg. 2008;34:289–294
  95. John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008;86:1227–1234discussion 34-5
  96. Slaughter MS, Naka Y, John R, et al. Postoperative heparin may not be required in transitioning patients with HeartMate II LVAD to long term warfarin therapy. J Heart Lung Transplant. 2010;[in press]
  97. Basra SS, Attallab AA, Wagle R, Loyalka R, Kar B. Infections in patients on continuous flow LVAD: epidemiology and role in causation of cerebrovascular accidents. J Heart Lung Transplant. 2009;28:S285
  98. Tulchinsky M. Lower gastrointestinal bleeding diagnosed by red blood cell scintigraphy in a patient with a left ventricular assist device. Clin Nucl Med. 2008;33:856–858
  99. Daas AY, Small MB, Pinkas H, Brady PG. Safety of conventional and wireless capsule endoscopy in patients supported with nonpulsatile axial flow Heart-Mate II left ventricular assist device. Gastrointest Endosc. 2008;68:379–382
  100. Garatti A, Bruschi G, Girelli C, Vitali E. Small intestine capsule endoscopy in magnetic suspended axial left ventricular assist device patient. Interact Cardiovasc Thorac Surg. 2006;5:1–4
  101. Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–109
  102. Malehsa D, Meyer AL, Bara C, Strüber M. Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Eur J Cardiothorac Surg. 2009;35:1091–1093
  103. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53:2162–2167
  104. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008;33:679–684
  105. Myers TJ, Bolmers M, Gregoric ID, Kar B, Frazier OH. Assessment of arterial blood pressure during support with an axial flow left ventricular assist device. J Heart Lung Transplant. 2009;28:423–427
  106. Frazier OH, Myers TJ, Gregoric ID, et al. Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation. 2002;105:2855–2860
  107. HeartMate II left ventricular assist system: patient handbook. Pleasanton, CA: Thoratec Corp; 2005.
  108. HeartMate II left ventricular assist system (LVAS) community living guide. Pleasanton, CA: Thoratec Corp; 2009.
  109. Myers TJ, Frazier OH, Mesina HS, Radovancevic B, Gregoric ID. Hemodynamics and patient safety during pump-off studies of an axial-flow left ventricular assist device. J Heart Lung Transplant. 2006;25:379–383
  110. Ueno A, Tomizawa Y. Cardiac rehabilitation and artificial heart devices. J Artif Organs. 2009;12:90–97
  111. MacIver J, Ross HJ, Delgado DH, et al. Community support of patients with a left ventricular assist device: The Toronto General Hospital experience. Can J Cardiol. 2009;25:e377–e381
  112. Oosterom A, de Jonge N, Kirkels JH, et al. End-stage heart failure and mechanical circulatory support: feasibility of discharge from hospital. Neth Heart J. 2007;15:45–50
  113. Drews TN, Loebe M, Jurmann MJ, Weng Y, Wendelmuth C, Hetzer R. Outpatients on mechanical circulatory support. Ann Thorac Surg. 2003;75:780–785; discussion 5
  114. El-Menyar AA. Multidisciplinary approach for circulatory support in patients with advanced heart failure. Expert Rev Cardiovasc Ther. 2009;7:259–262
  115. Seemuth SC, Richenbacher WE. Education of the ventricular assist device patient's community services. ASAIO J. 2001;47:596–601

 Conflict of Interest: See Disclosure Statement on page S36.

PII: S1053-2498(10)00043-4

doi: 10.1016/j.healun.2010.01.011

The Journal of Heart and Lung Transplantation
Volume 29, Issue 4, Supplement , Pages S1-S39 , April 2010

Article Tools

* Image Usage & Resolution